Orexo and Lyfebulb Announce Call for Digital Solutions to Treat Substance Use Disorder
Winning Entry to Receive USD 25,000 GrantUPPSALA, SWEDEN, AND NEW YORK, NY, USA, June 17[th], 2020: Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced that the Lyfebulb-Orexo Innovation Challenge: Digital Therapeutics for Substance Use Disorder is now accepting applications. The goal of the initiative is to seek novel digital solutions, in early stages of development, to address unmet needs in supporting successful, long-term recovery from alcohol and opioid use disorders. The